WEE1 and PKMYT1: gatekeepers of the G2/M checkpoint

WEE1 and PKMYT1 are structurally related serine/threonine kinases within the WEE kinase family whose shared substrate — the CDK1–Cyclin B complex — makes them the primary molecular brakes on mitotic entry. WEE1 phosphorylates CDK1 at Tyr15, while PKMYT1 phosphorylates CDK1 at Thr14; both modifications hold cells in G2 phase and prevent progression into mitosis until DNA replication is complete and damage is repaired. In replication stress-high tumors, where oncogene-driven fork stalling, aberrant origin firing, and chronic DNA damage accumulation are endemic, these kinases represent synthetically lethal targets: inhibiting them forces premature mitotic entry, which in already-stressed cells culminates in catastrophic genomic instability, apoptosis, or mitotic catastrophe.

A 2025 Chinese patent from the Shanghai Institute of Nutrition and Health (Chinese Academy of Sciences) provides detailed mechanistic evidence in pancreatic ductal adenocarcinoma (PDAC): PKMYT1 knockout enriches gene sets related to mitosis and G2/M checkpoints at the transcriptomic level, and the PKMYT1 inhibitor RP-6306 increases DNA damage accumulation and induces dose-dependent cell cycle arrest and apoptosis in PDAC cell models. CDK1 phosphorylation status — at Thr14 and Tyr15 — is used across multiple retrieved studies as a pharmacodynamic readout of inhibitor activity.

A patent from InSilico Medicine IP (China, 2024) extends the target indication list significantly: PKMYT1 overexpression is reported across gastric cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, glioblastoma, neuroblastoma, and colorectal cancer — all contexts where high proliferative stress and checkpoint dependency converge. Critically, a Merck Sharp & Dohme patent (Japan, 2016) establishes that low PKMYT1 expression in a tumor correlates with enhanced sensitivity to WEE1 inhibitor monotherapy, and that PKMYT1 knockdown by siRNA selectively restores that sensitivity while reducing inhibitory CDK1 phosphorylation. This WEE1/PKMYT1 synthetic relationship is the molecular foundation for the dual-inhibitor strategies now being actively IP-protected.

The DNA damage response (DDR) context is elaborated in filings from Debiopharm International S.A., which describe how cells facing both endogenous insults (stalled replication forks, reactive oxygen species) and exogenous insults (UV, ionizing radiation, chemical agents) rely on checkpoint pathways involving both WEE1 and PKMYT1. Simultaneous inhibition of both kinases is described as producing strong cytotoxic effects — a rationale consistent with the broader DDR inhibitor field, as documented by organisations including the National Cancer Institute.

Small-molecule inhibitor landscape: scaffolds, compounds, and assignees

The most active segment of the retrieved dataset is selective small-molecule inhibition of PKMYT1, with at least two distinct chemical scaffolds under active IP protection and a reference compound providing preclinical validation. WEE1 inhibitor programs are also represented, with a genetically defined patient population — H3K27M-mutant tumors — emerging as a key enrichment strategy.

PKMYT1 inhibitor scaffolds

InSilico Medicine IP (China) disclosed formula (A) heteroaromatic compounds in a 2024 CN patent, describing selective PKMYT1 targeting to block CDK1–Cyclin B activation in advanced solid tumors. MY-T Bio Limited’s 2026 WO patent discloses a structurally distinct biarylamide (BAA) scaffold — formula (I) compounds — with explicit claims covering CCNE1-amplified or overexpressed cancers and tumors with inactivation of FBXW7, PPP2R2A, or PPP2R1A. The reference compound RP-6306, documented in the Shanghai Institute of Nutrition and Health patent, has been used preclinically to demonstrate dose-dependent PKMYT1 hyperphosphorylation, reduced CDK1 phosphorylation, increased DNA damage accumulation, and apoptosis induction in PDAC cell models.

WEE1 inhibitor programs

Shanghai Yingpai Pharmaceuticals’ 2023 CN patent discloses WEE1 kinase inhibitors (formula I, II, or III compounds) specifically for treating cancers harboring histone H3K27M mutations — a genetically defined, replication stress-high population common in pediatric diffuse intrinsic pontine glioma and some adult gliomas. The patent also claims a companion diagnostic method using whole-exome sequencing to identify H3K27M mutation carriers. Merck Sharp & Dohme’s Japanese patent describes WEE1-1 and WEE1-2 as treatment agents, with PKMYT1 expression level in cancer cells positioned as a predictive biomarker for WEE1 inhibitor response — the clearest commercial articulation of the WEE1/PKMYT1 synthetic relationship in this dataset.

Combination strategies and synthetic lethality frameworks

Retrieved patent filings describe five distinct combination approaches, ranging from dual kinase inhibition to biomarker-guided synthetic lethality and chemotherapy augmentation — each grounded in the mechanistic logic that replication stress-high tumors carry multiple vulnerabilities that can be co-exploited.

WEE1 + PKMYT1 dual inhibition

The most explicitly patented combination in this dataset is the co-administration of a WEE1 inhibitor and a PKMYT1 inhibitor. Debiopharm International S.A. has secured multi-jurisdictional coverage — Australia (2026), WO (2025), and Taiwan (2025) — all claiming that simultaneous suppression of both G2/M checkpoint kinases produces cancer treatment effects exceeding either agent alone. The mechanistic rationale is that WEE1 and PKMYT1 each partially compensate for the other’s loss at the G2/M checkpoint, so dual blockade is required for maximal cytotoxicity. No clinical data are described in the retrieved text; the concept is patent-protected at the preclinical stage.

“Simultaneous inhibition of both WEE1 and PKMYT1 is described as producing strong cytotoxic effects — because each kinase partially compensates for the other’s loss at the G2/M checkpoint, dual blockade is required for maximal genomic catastrophe in replication stress-high tumors.”

PKMYT1 inhibitor + topoisomerase inhibitors or gemcitabine

MY-T Bio Limited’s 2026 WO patent explicitly claims that PKMYT1 inhibitors combined with topoisomerase I inhibitors, topoisomerase II inhibitors, or gemcitabine are indicated for CCNE1-amplified or FBXW7/PPP2R2A/PPP2R1A-inactivated cancers, and for p53/CDKN2A co-mutated tumors. This is consistent with the established rationale — well-documented in the broader oncology literature, including publications indexed by PubMed/NCBI — that replication stress-inducing chemotherapy agents synergize with checkpoint kinase inhibitors. The Shanghai Institute of Nutrition and Health data independently show that PKMYT1 knockout increases PDAC cell sensitivity to gemcitabine, strengthening the case for a PKMYT1 inhibitor + gemcitabine combination specifically in pancreatic cancer, where gemcitabine is standard of care.

Synthetic lethality-guided PKMYT1 targeting

Engine Biosciences Pte. Ltd. (Singapore) contributes a distinct modality: biomarker-guided PKMYT1 therapeutic agent deployment using synthetic lethal pairing. Multiple US and WO filings (2023–2024) describe methods for treating cancer by identifying biomarkers that form a synthetic lethal pair with PKMYT1. The mechanism is loss-of-function mutation-based: cancer cells harboring inactivating mutations in any of the paired biomarkers become dependent on PKMYT1 for survival, enabling selective targeting. The biomarker list includes CDKN2B, CSMD3, LRP1B, DMRTA1, PTPRD, ELAVL2, FAT1, CDH1, NF1, PPP6R2, PIM3, MAPK11, CDH10, PCDH15, and others.

Replication stress biomarker-guided immunotherapy combinations

The University of Texas System’s 2019 WO patent introduces a replication stress response defect (RSRD) gene expression signature applicable to patient stratification. RSRD-classified tumors exhibit depression of phosphorylated MDM2 in response to MEK inhibition and are linked to altered immune signaling. This signals an emerging interest in combining replication stress response biomarker profiling with immune checkpoint inhibitor selection and MEK inhibitor combinations — an approach that may complement, rather than compete with, direct kinase inhibitor strategies.

Biomarker stratification: from CCNE1 amplification to synthetic lethal panels

Biomarker stratification is central to the commercial positioning of every program in this dataset. Retrieved filings describe two parallel biomarker frameworks: molecular enrichment markers that predict inhibitor sensitivity, and synthetic lethal companion markers that define patient populations with tumor-specific PKMYT1 dependency.

Molecular enrichment biomarkers for PKMYT1 inhibitors

MY-T Bio Limited’s 2026 WO filing identifies CCNE1 amplification or overexpression, inactivation of FBXW7, inactivation of PPP2R2A or PPP2R1A, and p53/CDKN2A co-mutation as enrichment biomarkers for PKMYT1 inhibitor sensitivity — particularly in combination with topoisomerase inhibitors or gemcitabine. CCNE1 amplification is a well-established driver of replication stress, documented extensively in the oncology literature and in databases maintained by the National Cancer Institute and NCBI. FBXW7 and PP2A subunit inactivation both impair cell cycle regulation, creating additional checkpoint dependency that PKMYT1 inhibition can exploit.

WEE1 inhibitor enrichment: H3K27M mutation

Shanghai Yingpai Pharmaceuticals’ 2023 CN patent positions histone H3K27M mutation as the primary WEE1 inhibitor sensitivity biomarker, with companion diagnostic provisions using whole-exome sequencing. H3K27M mutations are most prevalent in pediatric diffuse intrinsic pontine glioma (DIPG) and a subset of adult gliomas — both contexts where replication stress is elevated and standard treatment options are limited. The patent’s companion diagnostic claim signals that the developers anticipate a genetically defined patient selection strategy from early development.

Synthetic lethal biomarker panel

Engine Biosciences’ framework introduces a broad panel of tumor suppressor and signal transduction gene loss-of-function mutations as companion biomarkers for PKMYT1 therapeutic agents. The panel — including CDKN2B, CSMD3, LRP1B, DMRTA1, PTPRD, ELAVL2, FAT1, CDH1, NF1, PPP6R2, PIM3, MAPK11, CDH10, and PCDH15 — creates both therapeutic opportunity and IP complexity. Academic researchers mapping cancer genome landscapes should assess co-occurrence frequencies of these mutations with PKMYT1 overexpression in relevant tumor types, using resources such as NCI’s cancer genomics databases.

Strategic implications for drug developers and IP strategists

The patent landscape described in this dataset carries concrete implications for drug developers, IP strategists, and investors evaluating programs in the WEE1/PKMYT1 space. Several strategic signals emerge directly from the retrieved filings.

The WEE1 + PKMYT1 combination concept is actively being IP-protected by Debiopharm International S.A. in multiple jurisdictions, signaling that the dual-inhibitor combination is viewed as a commercially distinct approach from WEE1 monotherapy. Drug developers should evaluate freedom-to-operate carefully around both single-agent and combination claims. PKMYT1 has a rapidly expanding small-molecule inhibitor chemistry landscape, with at least two distinct chemical scaffolds (heteroaromatic compounds from InSilico Medicine IP and biarylamide compounds from MY-T Bio Limited) and the reference compound RP-6306. IP strategists should monitor composition-of-matter filings in the WO and US jurisdictions for scaffold differentiation.

Pancreatic ductal adenocarcinoma and glioblastoma/H3K27M-mutant glioma appear to be among the highest-priority indications supported by this dataset, given the mechanistic data in PDAC and the genetically defined WEE1 inhibitor sensitivity signal in H3K27M-mutant tumors. Investors evaluating programs in these indications should weigh the preclinical strength of each claim against the absence of clinical translation data in the current dataset — no completed clinical trials, patient cohort data, or regulatory submissions were identified in retrieved results. Patent intelligence platforms such as PatSnap can help track the transition from preclinical IP to IND-enabling studies as this field evolves.

Companion diagnostic development should be co-initiated with IND-enabling studies: the biomarker stratification frameworks described — particularly the CCNE1/FBXW7/PP2A enrichment panel (MY-T Bio) and the H3K27M companion diagnostic (Shanghai Yingpai) — are already embedded in composition-of-matter and method-of-treatment claims. This integration of diagnostic and therapeutic IP reflects the broader industry trend toward precision oncology patient selection, consistent with regulatory frameworks described by the US FDA for companion diagnostics.